A Randomized, Double-blind, Placebo Controlled Trial of 4-Hydroxytamoxifen Gel for Reducing Breast Tissue Density in Women With BI-RADS Breast Density Categories C or D
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Afimoxifene (Primary)
- Indications Hyperplasia
- Focus Registrational; Therapeutic Use
- Acronyms 4WARD
- Sponsors BHR Pharma
- 27 Jan 2019 The trial has been discontinued in Spain, according to European Clinical Trials Database.
- 15 Jan 2019 Planned End Date changed from 30 Oct 2020 to 31 Mar 2019.
- 15 Jan 2019 Planned primary completion date changed from 30 Oct 2019 to 31 Mar 2019.